Literature DB >> 33368919

ESNM/ANMS consensus paper: Diagnosis and management of refractory gastro-esophageal reflux disease.

Frank Zerbib1, Albert J Bredenoord2, Ronnie Fass3, Peter J Kahrilas4, Sabine Roman5, Edoardo Savarino6, Daniel Sifrim7, Michael Vaezi8, Rena Yadlapati9, C Prakash Gyawali10.   

Abstract

Up to 40% of patients with symptoms suspicious of gastroesophageal reflux disease (GERD) do not respond completely to proton pump inhibitor (PPI) therapy. The term "refractory GERD" has been used loosely in the literature. A distinction should be made between refractory symptoms (ie, symptoms may or may not be GERD-related), refractory GERD symptoms (ie, persisting symptoms in patients with proven GERD, regardless of relationship to ongoing reflux), and refractory GERD (ie, objective evidence of GERD despite adequate medical management). The present ESNM/ANMS consensus paper proposes use the term "refractory GERD symptoms" only in patients with persisting symptoms and previously proven GERD by either endoscopy or esophageal pH monitoring. Even in this context, symptoms may or may not be reflux related. Objective evaluation, including endoscopy and esophageal physiologic testing, is requisite to provide insights into mechanisms of symptom generation and evidence of true refractory GERD. Some patients may have true ongoing refractory acid or weakly acidic reflux despite PPIs, while others have no evidence of ongoing reflux, and yet others have functional esophageal disorders (overlapping with proven GERD confirmed off therapy). In this context, attention should also be paid to supragastric belching and rumination syndrome, which may be important contributors to refractory symptoms.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  Barrett's esophagus; esophagitis; gastroesophageal reflux; laparoscopic fundoplication; pH-impedance monitoring; peptic stricture; proton pump inhibitor

Year:  2020        PMID: 33368919     DOI: 10.1111/nmo.14075

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  8 in total

1.  Best Practices in Treatment of Laryngopharyngeal Reflux Disease: A Multidisciplinary Modified Delphi Study.

Authors:  Afrin N Kamal; Shumon I Dhar; Thomas L Carroll; Lee M Akst; Jonathan M Bock; John O Clarke; Jerome R Lechien; Jacqueline Allen; Peter C Belafsky; Joel H Blumin; Walter W Chan; Ronnie Fass; P Marco Fisichella; Michael Marohn; Ashli K O'Rourke; Gregory Postma; Edoardo V Savarino; Michael F Vaezi
Journal:  Dig Dis Sci       Date:  2022-08-22       Impact factor: 3.487

2.  Optimal Wireless Reflux Monitoring Metrics to Predict Discontinuation of Proton Pump Inhibitor Therapy.

Authors:  Rena Yadlapati; C Prakash Gyawali; Melina Masihi; Dustin A Carlson; Peter J Kahrilas; Billy Darren Nix; Anand Jain; Joseph R Triggs; Michael F Vaezi; Leila Kia; Alexander Kaizer; John E Pandolfino
Journal:  Am J Gastroenterol       Date:  2022-06-10       Impact factor: 12.045

Review 3.  An update on current treatment strategies for laryngopharyngeal reflux symptoms.

Authors:  Amanda J Krause; Erin H Walsh; Philip A Weissbrod; Tiffany H Taft; Rena Yadlapati
Journal:  Ann N Y Acad Sci       Date:  2021-12-17       Impact factor: 6.499

4.  Omeprazole Treatment Failure in Gastroesophageal Reflux Disease and Genetic Variation at the CYP2C Locus.

Authors:  Ping Siu Kee; Simran D S Maggo; Martin A Kennedy; Murray L Barclay; Allison L Miller; Klaus Lehnert; Maurice A Curtis; Richard L M Faull; Remai Parker; Paul K L Chin
Journal:  Front Genet       Date:  2022-05-19       Impact factor: 4.772

Review 5.  Endoscopic anti-reflux therapy for gastroesophageal reflux disease.

Authors:  Enrique Rodríguez de Santiago; Eduardo Albéniz; Fermin Estremera-Arevalo; Carlos Teruel Sanchez-Vegazo; Vicente Lorenzo-Zúñiga
Journal:  World J Gastroenterol       Date:  2021-10-21       Impact factor: 5.742

6.  The Effect of Hyaluronic Acid and Chondroitin Sulphate-Based Medical Device Combined with Acid Suppression in the Treatment of Atypical Symptoms in Gastroesophageal Reflux Disease.

Authors:  Gaia Pellegatta; Benedetto Mangiavillano; Rossella Semeraro; Francesco Auriemma; Elisa Carlani; Alessandro Fugazza; Edoardo Vespa; Alessandro Repici
Journal:  J Clin Med       Date:  2022-03-29       Impact factor: 4.241

Review 7.  Review article: rethinking the "ladder" approach to reflux-like symptom management in the era of PPI "resistance" - a multidisciplinary perspective.

Authors:  A Pali S Hungin; Carmelo Scarpignato; Laurie Keefer; Maura Corsetti; Foteini Anastasiou; Jean W M Muris; Juan M Mendive; Peter J Kahrilas
Journal:  Aliment Pharmacol Ther       Date:  2022-04-22       Impact factor: 9.524

8.  Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients.

Authors:  Michael F Vaezi; Stephen Brunton; A Mark Fendrick; Colin W Howden; Christian Atkinson; Corey Pelletier; Rinu Jacob; Stuart J Spechler
Journal:  BMJ Open Gastroenterol       Date:  2022-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.